Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DS-1001b in chemotherapy- and radiotherapy-naive IDH1-mutated WHO grade II glioma
jRCT2080225243Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of safusidenib in glioma, sponsored by Daiichi Sankyo Co., Ltd. Started Jun 2020; status: completed.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on jRCT2080225243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225243.